We hear a lot about the need for new antibiotics. But what about the ones we already have?

In this episode, we sit down with Enrico Baraldi to explore the hidden world behind antibiotic markets. You hear how supply chains break, why withdrawals happen, and what it really takes to keep essential drugs available in countries like Sweden. You also get a look at the methods behind this research, the collaborations that make it possible, and some misconceptions that still shape the policy conversation.

What happens when economic models, healthcare needs, and global responsibilities collide? This conversation opens that door.

On our news section, we first cover a recent publication exploring the factors determining the colonization of the microbiome by antibiotic-resistant E. coli bacteria, and we bring an overview of the much-awaited Global Antibiotic Resistance Surveillance Report for 2025.

We wish you a peaceful and rewarding winter break, and see you again in the new year!

Check relevant links in the show notes here. ⁠ Follow our updates on ⁠twitter/X & Bluesky⁠ with #theAMRstudio hashtag! Theme music by ⁠Henrik Niss⁠.

Happy start of the summer, dear listeners! In this episode before our break, we interview Professor Tove Fall, a veterinarian turned epidemiologist working to unveil the molecular connections determining health and sickness. We learn about her path, how she developed her career to fit her interests and strong skills, and how important study design is. In the news section we cover a recent review about the vaginal microbiota, and a publication from one of our PhD students, who has been working on developing a new kind of inhibitor for metallo beta lactamases. We hope you enjoy this episode!

Check relevant links in the show notes here. Follow our updates on ⁠twitter/X & Bluesky⁠ with #theAMRstudio hashtag! Theme music by ⁠Henrik Niss⁠.

In this episode, we bring you an interview with Professor Elias Arnér from the Karolinska Institute. After a long international career in redox biology, Professor Arnér became CEO of Thioredoxin Systems, the company behind a potential new antibiotic with a novel target and mode of action: EbsArgent. We explore his background, the lessons he has learned, and what makes this new drug candidate so unique.

In the news section, Elin brings us a recent article on the resistance and potential collateral sensitivity of Ceftazidime-avibactam to treat P. aeruginosa strains. Eva shares the latest publication at our center, with PhD student Adrián González López’s work on the mechanisms behind FusB-mediated resistance in Staphylococcus aureus.

We hope you enjoy this month’s episode, and see you on the next one!

Check relevant links in the show notes here. Follow our updates on ⁠twitter/X & Bluesky⁠ with #theAMRstudio hashtag! Theme music by ⁠Henrik Niss⁠.